Table 4.
Secondary Efficacy Assessment: Analysis of Other Endoscopic Findings and Subjective Symptoms (Full-Analysis Set)
| Fexuprazan | Placebo | ||
|---|---|---|---|
| 20 mg once a day | 10 mg twice a day | ||
| Erosion healing | 56/102 (54.9)* | 59/102 (57.8)† | 38/96 (39.6) |
| Edema healing | 20/27 (74.1) | 22/30 (73.3) | 22/32 (68.8) |
| Redness improvement | 29/56 (51.8) | 26/54 (48.1) | 31/62 (50.0) |
| Hemorrhage improvement | 24/29 (82.8) | 16/17 (94.1) | 14/18 (77.8) |
| Symptom improvement | 63/102 (61.8) | 69/102 (67.6) | 68/96 (70.8) |
Data are presented as number (%).
*p=0.033 compared with the placebo group; †p=0.010 compared with the placebo group.